Reductil en es it fr

Reductil Brand names, Reductil Analogs

Reductil Brand Names Mixture

  • No information avaliable

Reductil Chemical_Formula


Reductil RX_link

Reductil fda sheet

Reductil FDA

Reductil msds (material safety sheet)

Reductil Synthesis Reference

No information avaliable

Reductil Molecular Weight

279.848 g/mol

Reductil Melting Point

191-192 oC

Reductil H2O Solubility

2.9 mg/mL (in pH 5.2 water)

Reductil State


Reductil LogP


Reductil Dosage Forms


Reductil Indication

For the treatment of obesity.

Reductil Pharmacology

Sibutramine is an orally administered agent for the treatment of obesity. Sibutramine exerts its pharmacological actions predominantly via its secondary (M1) and primary (M2) amine metabolites. The parent compound, sibutramine, is a potent inhibitor of serotonin and norepinephrine reuptake in vivo, but not in vitro. However, metabolites M1 and M2 inhibit the reuptake of these neurotransmitters both in vitro and in vivo. In human brain tissue, M1 and M2 also inhibit dopamine reuptake in vitro, but with ~3-fold lower potency than for the reuptake inhibition of serotonin or norepinephrine. Sibutramine, M1 and M2 exhibit no evidence of anticholinergic or antihistaminergic actions. In addition, receptor binding profiles show that sibutramine, M1 and M2 have low affinity for serotonin (5-HT1, 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C), norepinephrine (b, b1, b3, a1 and a2), dopamine (D1 and D2), benzodiazepine, and glutamate (NMDA) receptors. These compounds also lack monoamine oxidase inhibitory activity in vitro and in vivo.

Reductil Absorption

Rapid absorption following oral administration. Absolute bioavailability is not known, but at least 77% of a single oral dose of sibutramine is absorbed.

Reductil side effects and Toxicity

Side effects include dry mouth, anorexia, insomnia, constipation and headache.

Reductil Patient Information


Reductil Organisms Affected

Humans and other mammals